Drugs / Daratumumab and Hyaluronidase-fihj
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04956302 Background | Sep 2021 → Jun 2022 | plasma cell myeloma | Abdullah Khan | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daratumumab and Hyaluronidase-fihj | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04956302 ↗ |
| Route | Subcutaneous | “Given SC” NCT04956302 ↗ |